JY
CPIX icon

Jeff Yass’s Cumberland Pharmaceuticals CPIX Stock Holding History

Jeff Yass’s Portfolio CPIX Stock Details CPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$516K Buy
79,700
+62,900
+374% +$301K ﹤0.01% 9857
2026
Q1 		$54.6K Buy
16,800
+2,800
+20% +$10.8K ﹤0.01% 12616
2025
Q4 		$55.7K Buy
+14,000
New +$41.5K ﹤0.01% 11715

Other funds holding CPIX

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Jeff Yass's CPIX Position: Q1 2026 in Review

Jeff Yass sold out of Cumberland Pharmaceuticals (CPIX) in Q1 2026, closing a stake of 26,038 shares — an estimated $100K sold.

Jeff Yass first reported a position in CPIX in Q1 2023 and held it in 5 quarters. The position peaked at $122K in Q1 2025. 29 funds tracked by Wall St. Rank hold CPIX as of Q1 2026.

  • Jeff Yass reported no remaining Cumberland Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jeff Yass sold 26,038 Cumberland Pharmaceuticals shares in Q1 2026, an estimated $100K.
  • Jeff Yass first reported a position in Cumberland Pharmaceuticals in Q1 2023 and held it in 5 quarters.
  • Jeff Yass's Cumberland Pharmaceuticals position peaked at $122K in Q1 2025.
  • 29 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.